Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Benzer Materyaller

• Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
  Yazar:: Coates, LC, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
  Yazar:: McGagh, D, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
  Yazar:: Iain B. McInnes, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-10-01)
• Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
  Yazar:: Loredana Frasca, ve diğerleri
  Baskı/Yayın Bilgisi: (2018-09-01)
• Treat-to-target in PsA: methods and necessity
  Yazar:: Dures, E, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)